Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Unknown 9Recruiting 6Completed 6Withdrawn 1Terminated 1Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 112INDUSTRY 80OTHER_GOV 6NETWORK 6NIH 5

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 3Thoracic 2Gastrointestinal 1

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pathologic Complete Response 1

Interventions

Drug Therapy 10pembrolizumab 9Bevacizumab 9Radiotherapy 8Cyclophosphamide 8Carboplatin 8Oxaliplatin 7tislelizumab 6Surgical Procedures, Operative 6Docetaxel 6Cisplatin 6Capecitabine 6Paclitaxel 5Nivolumab 5Fluorouracil 5Control Groups 5fludarabine 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Docetaxel × Clear all
NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Nizhny Novgorod Regional Clinical Oncology Center

Phase 2 Recruiting
106 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Henan Cancer Hospital

Phase 3 Recruiting
812 enrolled
Breast

Breast Neoplasms

NCT07050043 2025-07-03

LEDANG

Hospital Sultanah Bahiyah

Phase 3 Recruiting
123 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
369 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Henan Cancer Hospital

Phase 2 Recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡